10 completed, 2 terminated, 1 active not recruiting, 1 withdrawn. 14 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 10, Terminated 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 4, Terminated 1, Withdrawn 1 |
Follow Mastocytosis: new trials by email Literature Review of Mastocytosis trials Research Report on Mastocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies BLU-263, Azacitidine - Advanced Systemic Mastocytosis | Phase 1 | Terminated | Blueprint Medicines Corporation | 9 | 2023-09-25 | 2025-04-10 |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies MGD024 - Leukemia, Acute Myeloid, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | MacroGenics | 130 | 2022-07-13 | 2026-07-28 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II - High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | GT Biopharma, Inc. | 12 | 2020-01-01 | 2022-11-10 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 AK002 - Indolent Systemic Mastocytosis | Phase 1 | Completed | Allakos Inc. | 25 | 2016-06-01 | 2019-03-13 |
| (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies Avapritinib - Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease | Phase 1 | Completed | Blueprint Medicines Corporation | 86 | 2016-03-10 | 2023-03-17 |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies DCC-2618 - Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis | Phase 1 | Completed | Deciphera Pharmaceuticals, LLC | 282 | 2015-11-01 | 2023-12-13 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer donor natural killer cell infusion - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders | Phase 1 / Phase 2 | Completed | Asan Medical Center | 47 | 2009-01-01 | 2013-02-20 |
| A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies Nilotinib - Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 507 | 2005-04-01 | 2021-06-29 |
| Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer PS-341, Doxil, Velcade - Breast Cancer, Leukemia | Phase 1 / Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 107 | 2001-05-01 | 2012-05-18 |
| Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer total-body irradiation, fludarabine phosphate, cyclosporine - Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 21 | 2000-05-01 | 2020-01-21 |
| Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Edetate Calcium Disodium, Ethanol, Trimethoprim-sulfamethoxazole - Chronic Myeloproliferative Disorders, Infection | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2013-02-15 |
Leukemia, Mast-Cell (10) · Leukemia, Hairy Cell (8) · Leukemia, Myeloid, Acute (8) · Mastocytosis, Systemic (8) · Burkitt Lymphoma (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Hodgkin Disease (6) · Intraocular Lymphoma (6) · Leukemia, Large Granular Lymphocytic (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Leukemia, Myelomonocytic, Chronic (6) · Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Extranodal NK-T-Cell (6) · Lymphoma, Follicular (6) · Lymphoma, Large B-Cell, Diffuse (6)
Immune System Diseases (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Hematologic Diseases (13) · Hemic and Lymphatic Diseases (13) · Leukemia, Myeloid (13) · Mast Cell Activation Disorders (13) · Bone Marrow Diseases (11) · Disease Attributes (10) · Leukemia (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Chronic Disease (9) · Immunoproliferative Disorders (9)
AK002 (1) · Acetaminophen (1) · Azacitidine (1) · Bortezomib (1) · Calcium Dobesilate (1) · Cyclosporine (1) · Dexamethasone (1) · Diphenhydramine (1) · Edetic Acid (1) · Ethanol (1) · Ibuprofen (1) · MK 2206 (1) · Mycophenolic Acid (1) · Pentetic Acid (1) · Peripheral Blood Stem Cell Transplantation (1)
Blueprint Medicines Corporation (2) · National Cancer Institute (NCI) (2) · Allakos Inc. (1) · Asan Medical Center (1) · City of Hope Medical Center (1) · Deciphera Pharmaceuticals, LLC (1) · Fred Hutchinson Cancer Center (1) · GT Biopharma, Inc. (1) · M.D. Anderson Cancer Center (1) · MacroGenics (1) · Novartis Pharmaceuticals (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (11) · Germany (4) · Canada (3) · Italy (3) · Netherlands (3) · United Kingdom (3) · Belgium (2) · France (2) · Norway (2) · South Korea (2) · Spain (2) · Australia (1) · Austria (1) · Denmark (1) · Finland (1)
David Maloney (1) · Elizabeth C. Dees, MD (1) · Frank Perabo, MD, PhD (1) · Ibrahim T Aldoss (1) · John Deeken (1) · Jorge Cortes, MD (1) · Kyoo H. Lee, MD (1) · Marcus Maurer, MD (1) · Mark B Juckett, MD (1) · Maryam Fouladi (1) · Patrick Chaftari, MD (1) · Robert Z. Orlowski, MD, PhD (1)
PMID 16775235, PMID 17715389, PMID 18327587, PMID 21098399, PMID 22259028, PMID 23547655, PMID 24057647, PMID 24474568, PMID 26002753, PMID 32499241, PMID 32804590, PMID 34873347, PMID 35622074, PMID 35640224, PMID 35790816
2015 (1), P01CA078902 (1), P30CA015704 (1), P30CA033572 (1), U01CA097452 (1), U01CA121947 (1)